FibroBiologics, Inc. Common Stock (FBLG) Stock
Fundamentals
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 1 articles
published over the past 14 days
About FibroBiologics, Inc. Common Stock
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter O'Heeron | Founder, Chairperson & CEO | 1964 |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer | 1970 |
| Mr. Ruben A. Garcia J.D. | General Counsel | 1977 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -74.4 | -0.8 | -20.5 | -15.2 | -23.1 | +117.7 | -34.1 |
Corporate actions
Upcoming
No upcoming corporate actions for FBLG




